Bank of New York Mellon’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-238,464
| Closed | -$3.61M | – | 4607 |
|
|
2022
Q3 | $3.61M | Buy |
238,464
+10,405
| +5% | +$121K | ﹤0.01% | 2487 |
|
|
2022
Q2 | $1.71M | Buy |
228,059
+6,648
| +3% | +$46.9K | ﹤0.01% | 2920 |
|
|
2022
Q1 | $2.02M | Buy |
221,411
+21,757
| +11% | +$168K | ﹤0.01% | 2942 |
|
|
2021
Q4 | $1.4M | Sell |
199,654
-337
| -0.2% | -$3.53K | ﹤0.01% | 3192 |
|
|
2021
Q3 | $2.28M | Buy |
199,991
+10,793
| +6% | +$158K | ﹤0.01% | 2912 |
|
|
2021
Q2 | $3.03M | Sell |
189,198
-24,648
| -12% | -$423K | ﹤0.01% | 2746 |
|
|
2021
Q1 | $3.82M | Sell |
213,846
-3,314
| -2% | -$57.2K | ﹤0.01% | 2572 |
|
|
2020
Q4 | $2.93M | Sell |
217,160
-1,058,112
| -83% | -$12.8M | ﹤0.01% | 2623 |
|
|
2020
Q3 | $15M | Sell |
1,275,272
-9,548
| -0.7% | -$116K | ﹤0.01% | 1645 |
|
|
2020
Q2 | $19M | Sell |
1,284,820
-65,938
| -5% | -$975K | 0.01% | 1476 |
|
|
2020
Q1 | $18.2M | Sell |
1,350,758
-36,924
| -3% | -$701K | 0.01% | 1346 |
|
|
2019
Q4 | $33.5M | Buy |
1,387,682
+43,633
| +3% | +$904K | 0.01% | 1238 |
|
|
2019
Q3 | $25.8M | Sell |
1,344,049
-219,672
| -14% | -$5.03M | 0.01% | 1378 |
|
|
2019
Q2 | $46.2M | Sell |
1,563,721
-169,359
| -10% | -$6.53M | 0.01% | 1023 |
|
|
2019
Q1 | $82.3M | Buy |
1,733,080
+266,961
| +18% | +$11.8M | 0.02% | 687 |
|
|
2018
Q4 | $52.9M | Buy |
1,466,119
+835,304
| +132% | +$39.2M | 0.02% | 841 |
|
|
2018
Q3 | $38.8M | Buy |
630,815
+203
| +0% | +$13.1K | 0.01% | 1200 |
|
|
2018
Q2 | $42.6M | Buy |
630,612
+32,820
| +5% | +$1.84M | 0.01% | 1113 |
|
|
2018
Q1 | $32.4M | Sell |
597,792
-15,513
| -3% | -$868K | 0.01% | 1255 |
|
|
2017
Q4 | $36.6M | Buy |
613,305
+63,030
| +11% | +$3.82M | 0.01% | 1182 |
|
|
2017
Q3 | $26.7M | Buy |
550,275
+113,320
| +26% | +$6.18M | 0.01% | 1396 |
|
|
2017
Q2 | $23M | Buy |
436,955
+171,879
| +65% | +$8M | 0.01% | 1469 |
|
|
2017
Q1 | $12M | Buy |
265,076
+68,360
| +35% | +$3.05M | ﹤0.01% | 1863 |
|
|
2016
Q4 | $7.45M | Buy |
196,716
+37,219
| +23% | +$1.41M | ﹤0.01% | 2118 |
|
|
2016
Q3 | $6.02M | Buy |
159,497
+27,351
| +21% | +$603K | ﹤0.01% | 2148 |
|
|
2016
Q2 | $2.33M | Buy |
132,146
+1,312
| +1% | +$21.2K | ﹤0.01% | 2618 |
|
|
2016
Q1 | $1.59M | Buy |
130,834
+3,679
| +3% | +$58.2K | ﹤0.01% | 2792 |
|
|
2015
Q4 | $3.1M | Sell |
127,155
-1,679
| -1% | -$39.2K | ﹤0.01% | 2463 |
|
|
2015
Q3 | $2.29M | Buy |
128,834
+29,067
| +29% | +$526K | ﹤0.01% | 2655 |
|
|
2015
Q2 | $1.76M | Buy |
99,767
+10,027
| +11% | +$184K | ﹤0.01% | 3001 |
|
|
2015
Q1 | $2.81M | Sell |
89,740
-1,591
| -2% | -$46.1K | ﹤0.01% | 2630 |
|
|
2014
Q4 | $2.67M | Buy |
91,331
+11,808
| +15% | +$299K | ﹤0.01% | 2665 |
|
|
2014
Q3 | $1.65M | Buy |
79,523
+40,931
| +106% | +$807K | ﹤0.01% | 3012 |
|
|
2014
Q2 | $956K | Buy |
38,592
+5,681
| +17% | +$98.4K | ﹤0.01% | 3339 |
|
|
2014
Q1 | $697K | Buy |
32,911
+9,261
| +39% | +$187K | ﹤0.01% | 3455 |
|
|
2013
Q4 | $425K | Buy |
+23,650
| New | +$308K | ﹤0.01% | 3636 |
|
Bank of New York Mellon's AERI Position: Q4 2022 in Review
Bank of New York Mellon sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 238,464 shares — an estimated $3.61M sold.
Bank of New York Mellon first reported a position in AERI in Q4 2013 and held it in 36 quarters. The position peaked at $82.3M in Q1 2019. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Bank of New York Mellon reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Bank of New York Mellon sold 238,464 Aerie Pharmaceuticals shares in Q4 2022, an estimated $3.61M.
- Bank of New York Mellon first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 36 quarters.
- Bank of New York Mellon's Aerie Pharmaceuticals position peaked at $82.3M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.